Dashboard
Manage Tickers

MNPR


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-home-depot-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday
This Home Depot Analyst Is No Longer Bulli...
11/14/2025 12:10:02

raymond-james-downgrades-monopar-therapeutics-to-outperform-lowers-price-target-to-123
Raymond James Downgrades Monopar Therapeut...
11/14/2025 11:54:30

Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers t...

chardan-capital-maintains-buy-on-monopar-therapeutics-maintains-100-price-target
Chardan Capital Maintains Buy on Monopar T...
11/13/2025 21:15:01

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.

monopar-therapeutics-q3-eps-048-misses-045-estimate
Monopar Therapeutics Q3 EPS $(0.48) Misses...
11/13/2025 13:06:41

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate o...

chardan-capital-maintains-buy-on-monopar-therapeutics-raises-price-target-to-100
Chardan Capital Maintains Buy on Monopar T...
11/10/2025 12:19:47

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from ...

leerink-partners-initiates-coverage-on-monopar-therapeutics-with-outperform-rating-announces-price-target-of-115
Leerink Partners Initiates Coverage On Mon...
11/10/2025 11:59:31

Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating a...

reported-sunday-monopar-presents-phase-2-data-showing-rapid-copper-balance-improvement-in-wilson-disease-patients-on-tiomolybdate-choline-at-aasld-2025
Reported Sunday, Monopar Presents Phase 2 ...
11/10/2025 08:10:57

this-monopar-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday
This Monopar Therapeutics Analyst Begins C...
10/13/2025 12:25:51

barclays-initiates-coverage-on-monopar-therapeutics-with-overweight-rating-announces-price-target-of-125
Barclays Initiates Coverage On Monopar The...
10/13/2025 12:05:47

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announce...

raymond-james-maintains-strong-buy-on-monopar-therapeutics-raises-price-target-to-142
Raymond James Maintains Strong Buy on Mono...
10/06/2025 16:59:18

Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price targ...

oppenheimer-maintains-outperform-on-monopar-therapeutics-raises-price-target-to-115
Oppenheimer Maintains Outperform on Monopa...
10/02/2025 13:31:55

Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price ta...

hc-wainwright--co-maintains-buy-on-monopar-therapeutics-raises-price-target-to-105
HC Wainwright & Co. Maintains Buy on Monop...
09/29/2025 14:09:37

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the ...

piper-sandler-maintains-overweight-on-monopar-therapeutics-raises-price-target-to-95
Piper Sandler Maintains Overweight on Mono...
09/25/2025 16:52:30

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target...

crowdstrike-to-rally-around-26-here-are-10-top-analyst-forecasts-for-thursday
CrowdStrike To Rally Around 26%? Here Are ...
09/25/2025 12:16:13

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

btig-maintains-buy-on-monopar-therapeutics-raises-price-target-to-104
BTIG Maintains Buy on Monopar Therapeutics...
09/25/2025 11:56:35

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 t...

chardan-capital-maintains-buy-on-monopar-therapeutics-raises-price-target-to-85
Chardan Capital Maintains Buy on Monopar T...
09/25/2025 11:52:13

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from...

reported-earlier-monopar-highlights-journal-of-hepatology-publication-confirming-alxn1840-rapidly-improved-copper-excretion-in-wilson-disease-patients
Reported Earlier ,Monopar Highlights Journ...
09/24/2025 06:25:51

reported-earlier-monopar-therapeutics-prices-135m-underwritten-offering-of-1034433-common-stock-and-pre-funded-warrants-at-6767-per-share-plans-35m-buyback-of-shares-from-tactic-pharma
Reported Earlier, Monopar Therapeutics Pri...
09/24/2025 06:25:09

lake-street-initiates-coverage-on-monopar-therapeutics-with-buy-rating-announces-price-target-of-106
Lake Street Initiates Coverage On Monopar ...
09/23/2025 14:38:19

Lake Street initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $106.

chardan-capital-maintains-buy-on-monopar-therapeutics-maintains-60-price-target
Chardan Capital Maintains Buy on Monopar T...
09/16/2025 11:11:37

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $60 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION